Lacosamid Intas (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing hyperexcitable neurons, it reduces repetitive firing and the spread of seizure activity, thereby contributing to seizure suppression.

The specific dose of Lacosamid Intas is determined by the prescribing healthcare professional based on the individual patient's condition, response, and tolerability. Dosing information should be obtained from the prescriber’s instructions and the product labeling.

The safety of lacosamide in pregnancy and lactation has not been fully established. Clinicians should evaluate the potential benefits against possible risks before prescribing to pregnant or nursing women, and discuss alternative options when appropriate.

To request Lacosamid Intas, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacosamide belongs to the sodium channel blocker class, offering a distinct mechanism that enhances slow inactivation of sodium channels. Compared with other antiepileptics that act on fast inactivation or other pathways, lacosamide may provide complementary seizure control when used as add‑on therapy, especially in patients with refractory focal seizures.

Lacosamid Intas should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lacosamid Intas is administered orally, typically as a tablet taken with or without food. The exact administration schedule and any special instructions should follow the prescribing clinician’s guidance and the product’s labeling.

Serious risks include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, and the emergence of suicidal thoughts or behaviors. Patients should be monitored for these events, and any concerning symptoms should prompt immediate medical evaluation.

Lacosamid Intas is contraindicated in patients with known hypersensitivity to lacosamide or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, uncontrolled arrhythmias, or those taking other medications that markedly affect sodium channel function.